Coronavirus

Encouraging national trends hide a complex picture of “100 epidemics,” some rising, some falling

The Food and Drug Administration held no advisory meeting on antiviral, and the European Union signed contract without knowing of failed trial

A trial showed that nitazoxanide, an antiparasitic drug, lowers virus levels in patients. Scientists say it’s irrelevant

For Akiko Iwasaki, the pandemic has brought new research priorities—and new urgency

Some committee members warn against emergency use of candidates not definitively proven safe or effective

On this week’s show: Ethical dilemmas will abound for efficacy trials that continue after one COVID-19 vaccine proves itself, and turning plastic bags into biodegradable detergents

Cold-causing adenovirus used in four experimental COVID-19 vaccines increased risk of HIV infection when used in AIDS vaccine trials

Solidarity fails to find mortality benefits in four treatments—but the global trial itself wins praise

On this week’s show: A profile of a scientist fighting for her people to be counted, and quantifying how the heart uses fuel

Trisha Greenhalgh argues COVID-19 shows how too much weight on evidence-based medicine can be the enemy of good policy

New treatment protocol recommends butter, herbs, and other Ayurvedic remedies for coronavirus patients

Ethical dilemmas will abound for efficacy trials that continue after one vaccine proves itself

How physician Deborah Birx’s unreasonable demands for hospital data created a “debacle” at CDC

Host variants boost severity risk, may point to drug options

New methods could make systematic reviews relevant during health emergencies

CRISPR-based approach is much faster than current diagnostics, but does have some limitations